SHINE Technologies has entered into an agreement to acquire the SPECT business from Lantheus, enhancing its distribution channels for medical isotopes. This acquisition includes facilities in North Billerica, Massachusetts, and is expected to create synergies that bolster SHINE's leadership in the nuclear medicine market. The combined efforts will expand SHINE's product portfolio and improve patient access to critical medical isotopes, including those used in diagnosing and treating diseases like cancer. SHINE aims to operate its Chrysalis facility as the largest isotope production site globally, supporting sustainable and reliable isotope supply.
Tue, 06 May 2025 20:01:00 GMT | PR Newswire